TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Transmission rates of congenital toxoplasmosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: mean weight loss at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in hearing thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMFM‐88D score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apolipoprotein B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: exit-site infection (ESI) rate
Endpoint domain: Adverse events/effects
Primary endpoint: ESI-free catheter survival
Endpoint domain: Mortality/survival
Primary endpoint: migration rate
Endpoint domain: Adverse events/effects
Primary endpoint: modified fatigue impact scale (MFIS) score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Immunological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequencies of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: alcohol-related outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient between assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total morphine consumed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Baroreceptor sensitivity (BRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: weight gain velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: head circumference increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration after intubation to achieve no pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIHSS score at 7 and 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified Rankin Scale (mRS) at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pulmonary artery pressure (mPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to maximum insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum metabolic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GIR-AUC(0-120)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RLS symptoms and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days to p.o. liquids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: amount of analgesic usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean operative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cure rates for bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttreatment vulvovaginal candidiasis rates
Endpoint domain: Adverse events/effects
Primary endpoint: event-free time for stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: event-free time for major bleeding
Endpoint domain: Mortality/survival
Primary endpoint: event-free time for intracranial bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Eczema Area and Severity Index (EASI) score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total therapeutic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal lobe volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLAIR hyperintensity volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PTH secretion response to Pi load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Calciuria levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 25‐OH‐D(3) serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Primary cardiac end-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of adverse obstetrical and neonatal outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: locomotor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: object control skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in procollagen type 1 N-terminal propeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum C-telopeptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death/nonfatal MI
Endpoint domain: Mortality/survival
Primary endpoint: Rates of child maltreatment
Endpoint domain: Adverse events/effects
Primary endpoint: Child protective services reports
Endpoint domain: Adverse events/effects
Primary endpoint: Instances of medical neglect
Endpoint domain: Adverse events/effects
Primary endpoint: purchasing intentions for SSB
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceptions of soda companies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: analgesic onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved analgesia for the first 15 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcription error rate
Endpoint domain: Adverse events/effects
Primary endpoint: Major adverse events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Aneurysm sac diameter decrease >5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of acute rejection
Endpoint domain: Mortality/survival
Primary endpoint: incidence of composite events (acute rejection, graft loss, or death)
Endpoint domain: Mortality/survival
Primary endpoint: mean time to acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive accuracy of general practitioner's assessment for thrombolytic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-operative decrease in haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: preinjection IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: change in IOP postinjection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: difference in IOP between the two eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Physical inactivity at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostate Symptom Score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum urinary flow rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reflux symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial gastric 3 cycle per minute activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lengthening effect on the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy based on geometric mean tick counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent efficacy over all post-enrolment visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rates for lotilaner and fipronil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: performance-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: mean number of sites with bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kt/V values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urea extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta2‐m extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of adequately depicted run-off arteries per calf
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: motor-evoked potential frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in obesity (BMI > 30 kg/m(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in target systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in general health status scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in levels of anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in time spent being physically active
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Development of meniscal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean severity score of meniscal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adverse events rates
Endpoint domain: Adverse events/effects
Primary endpoint: C(max,ss) of telmisartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(τ,ss) of telmisartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T(max) of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent t((1/2)) of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HGPIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active inflammation incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic inflammation incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total carotenoid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical resolution of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial internal rotation laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior tibial translation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of bacteria in otorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incremental QALY
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference in 2-year Disease-Free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Difference in 5-year Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Total bacterial counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Counts of specific bacterial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool frequency or consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Effectiveness of Vacurette biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in cystoid macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel revascularization (TVR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in health status at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence about returning to activities 1 month after discharge
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Fewer further treatment needs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anterior continuous curvilinear capsulorhexis (ACCC) area shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior capsule fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior capsulorhexis (PCCC) area change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intracellular water, extracellular water and total body water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bacterial count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of dementia
Endpoint domain: Mortality/survival
Primary endpoint: Uptake of recommended core treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Perceived Effect (GPE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiac MIBG uptake based on H/M
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Admissions to the antepartum service
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Amount of bloody drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Grade 3+ late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of complications
Endpoint domain: Adverse events/effects
Primary endpoint: BCG scar prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scar size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPD reaction size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: withdrawal severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seroprotection/seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of solicited/unsolicited severe adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of hazardous alcohol consumption during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in serum alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in social quality of life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Radicular blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of pneumothorax
Endpoint domain: Mortality/survival
Primary endpoint: AD incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: GH secretion inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PRL secretion inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin secretion inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean true gestational age at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: treatment response rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cost per successfully treated attack
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Regained lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ACR 20, 50 and 70 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Disease Activity Score (DAS28 < 3.2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean DPRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HADS anxiety subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MOS sleep interference score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean Arterial Pressure (MAP) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End-tidal CO2 (ETCO2) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healing time after skin grafting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of men with excessive consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in gamma-glutamyltransferase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative morphine consumption in postoperative 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of DHEA sulfate and androstanediol glucuronide morning serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progress in pubic hair growth from Tanner stage I‐III to II‐V
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in psychological well-being as measured by Symptom Check‐List‐90‐R scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preservation of endogenous insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Need for exogenous insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diabetes knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Regular exercise increase
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: serum cystatin C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: anterior capsule opening area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOL decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal oxygen uptake (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Significant pain relief (>or= 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of intra-abdominal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of intra-abdominal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to an oral anti‐diabetic medication regime
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean colony-forming units (CFUs) of Candida albicans and gram-negative bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: semen density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: class A + B semen quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: 1-h activity ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean visual acuity letter score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCT-measured central subfield thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of retinal thickening in the macular grid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes